Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation (ASAPF) delivers innovative spinal implant technologies focused on minimally invasive surgical solutions and regenerative approaches. This news hub provides investors and healthcare professionals with essential updates on the company’s financial developments, product milestones, and clinical advancements.
Access timely announcements including quarterly earnings reports, regulatory approvals for new devices, and strategic partnerships within the medical device sector. Our curated collection ensures transparent tracking of Aurora Spine’s progress in improving spinal care through screwless implant systems and biointegrated solutions.
Discover press releases covering FDA clearances, research collaborations, and executive leadership changes that shape the company’s trajectory. All content is verified for accuracy and relevance to support informed decision-making about ASAPF’s market position and technological contributions.
Bookmark this page for streamlined access to Aurora Spine’s latest developments in spinal healthcare innovation. Check regularly for updates on patent filings, clinical trial results, and industry recognition of their patient-focused medical devices.
Aurora Spine Corporation (ASAPF) announced the enrollment of initial patients in a pivotal multi-center study for its ZIP® Interspinous Fixation device, targeting back pain due to degenerative disc disease. The REFINE Screwless™ ZIP Study aims to evaluate the device across 10 surgical sites in the US with an expected enrollment of approximately 100 patients. This minimally invasive alternative to traditional spinal surgery promises reduced recovery time and increased patient mobility. The ZIP System, cleared by the FDA in 2013, has been used in over 5,000 procedures globally, demonstrating its safety and effectiveness.
Aurora Spine Corporation has received FDA 510(k) Clearance for its DEXA-C, the first cervical cage utilizing patented DEXA Technology™ designed to match patient bone density. This innovation aims to enhance spinal surgery outcomes by promoting faster bone growth and providing superior fixation. The DEXA-C line represents a significant advancement in personalized implants, moving away from traditional one-size-fits-all solutions. Experts, including Dr. Sebastian Koga, praise its potential to revolutionize interbody fusion and replace existing materials.
Aurora Spine Corporation (OTCQB: ASAPF) has announced its participation in the Alliance Global Partners’ Virtual MedTech Summer Conference on July 29, 2021. President and CEO Trent Northcutt expressed gratitude for the opportunity to present the company’s innovative, minimally invasive spinal implant technologies aimed at enhancing surgical outcomes. This event will feature one-on-one investor meetings, and interested investors can arrange meetings through Alliance Global Partners. Aurora Spine aims to expand its market presence by introducing new products targeting pain management.
Aurora Spine Corporation (OTCQB: ASAPF) will participate in the Third Annual ASPN Conference from July 22-25, 2021, at the Loews Miami Beach Hotel. The company will sponsor a breakfast symposium and a hands-on training lab featuring 19 lab stations for pain procedures and minimally invasive spinal surgery. Course directors include renowned surgeons, enhancing education on Aurora's products. Additionally, on July 23, Aurora will showcase its pain products in a joint breakfast and product theater.
CEO Trent Northcutt emphasizes the importance of in-person events for engaging with healthcare professionals post-pandemic.
Aurora Spine Corporation (ASAPF) will participate in the Lytham Partners Summer 2021 Investor Conference from June 14-16, 2021. President and CEO Trent Northcutt is set to deliver a presentation on June 14 at 12:30 PM ET. The presentation will be accessible via a webcast on the company's website. Additionally, Northcutt and CFO Chad Clouse will be available for one-on-one meetings during the event. Northcutt expressed enthusiasm about sharing Aurora’s advancements in innovative spinal implant technologies with investors.
Aurora Spine Corporation (OTCQB: ASAPF) announced IRB approval for a multicenter study of its SiLOTM SI Fusion System, aimed at patients needing sacroiliac joint fusion surgery. The study will involve up to 11 investigative sites in the U.S., focusing on up to 60 subjects. The SiLO system is designed to stabilize the SI joint with bone allograft implants. The primary outcomes will evaluate changes in pain levels and quality of life for patients. This clinical evidence is intended to support the system's efficacy and safety in treating SI joint pain.
Aurora Spine Corporation (OTCQB: ASAPF) has obtained Institutional Review Board (IRB) approval for a multicenter clinical study of its ZIP® Interspinous Fixation device, aimed at treating back pain from degenerative disc disease. This study will involve 100 patients, with results expected within the year. The ZIP® device has already been used in over 5,000 procedures globally, showcasing its effectiveness in outpatient settings. Aurora partners with Celéri Health for data management, intending to enhance the treatment of chronic back pain through rigorous clinical research.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation in the Lytham Partners Spring 2021 Investor Conference on March 30, 2021, at 1:15 PM ET. The company's President & CEO, Trent Northcutt, and CFO, Chad Clouse, will present and engage in virtual one-on-one meetings from March 30 to April 1, 2021. A live webcast of the presentation will be accessible on their website, with an archived version available later. Aurora Spine focuses on innovative spinal implant technologies and pain management solutions.
Aurora Spine Corporation announced the launch of its proprietary SiLO™ Posterior SI Joint Fusion System, designed for posterior sacroiliac joint fusion. This innovative system aims to enhance surgical outcomes through a single graft method made of human cortical bone. The Company also released a biomechanical whitepaper demonstrating that the SiLO graft effectively immobilizes the sacroiliac joint better than traditional rectangular grafts. The SI joint fusion market is projected to grow significantly, with an estimated value of $150 million to $250 million globally in 2019, indicating a high potential for Aurora's growth.
Aurora Spine Corporation announced that its common shares are now trading on the OTCQB Venture Market under the symbol ASAPF, enhancing accessibility for US investors. This move is aimed at improving Aurora's status as a publicly traded company and boosting investor awareness, which the company began in 2020. The management foresees this listing as timely, coinciding with plans to launch several new proprietary products in 2021.
For more information, visit OTC Markets.
FAQ
What is the current stock price of Aurora Spine (ASAPF)?
What is the market cap of Aurora Spine (ASAPF)?
